{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-155830","form_type":"8-K","ticker":"INO","cik":"0001055726","company_name":"INOVIO PHARMACEUTICALS, INC.","filed_at":"2025-07-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.216380+00:00","generated_at":"2026-05-18T09:14:35.515355+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Inovio prices $25M public offering of common stock and warrants","bullets":["Gross proceeds of $25M from 14,285,715 shares and accompanying Series A/B warrants at $1.75/unit.","Net proceeds expected ~$22.5M after underwriting discounts and expenses; closing on July 7, 2025.","Underwriters have 30-day option for up to 2,142,857 additional shares and warrants.","Series A warrants expire 12 months from issuance or 30 days after FDA acceptance of BLA for INO-3107.","Series B warrants expire 5 years; Piper Sandler sole book-runner, Oppenheimer passive bookrunner."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-155830","json":"https://secwatch.observer/filing/0001193125-25-155830.json","markdown":"https://secwatch.observer/filing/0001193125-25-155830.md","text":"https://secwatch.observer/filing/0001193125-25-155830.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1055726/000119312525155830/0001193125-25-155830-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1055726/000119312525155830/d15686d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:14:35.515355+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}